Trials
Search / Trial NCT05636696

COMPANION: A Couple Intervention Targeting Cancer-related Fatigue

Launched by MARIËT HAGEDOORN · Dec 2, 2022

Trial Information

Current as of February 05, 2025

Active, not recruiting

Keywords

Chronic Cancer Related Fatigue Cancer Behavioral Intervention Mindfulness Intervention Dyadic Intervention Pilot Partners Spouses

ClinConnect Summary

This is a 1-arm pilot trial. Recruitment will take place via a hospital, the Helen Dowling Institute and self-referral. The target is to include 34 couples (i.e. 68 participants). All participating cancer patients and their partners will be allocated to the couple mindfulness-based cognitive behavioral therapy, provided via internet (couple eMBCT), called 'COMPANION' (in Dutch: 'Samen Minder Moe') Assessments include three questionnaires (i.e. before starting the intervention (T0), after completing the intervention (T1), and 1 month after T1 (T2)). The assessments include also weekly diarie...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Only couples are eligible for participation. In order to be eligible, the couple must meet each of the following criteria:
  • 1. The patient has received a cancer diagnosis (all malignancies will be included);
  • 2. The patient completed cancer treatment with either curative or palliative intent ≥ 3 months earlier. Patients who currently receive hormone therapy are eligible;
  • 3. The patient experiences severe levels of fatigue (score of ≥ 35 on the Checklist Individual Strength, subscale fatigue severity (CIS-fatigue));
  • 4. The patient has been suffering from severe fatigue for ≥ 3 months (as self-reported by the patient);
  • 5. The patient was ≥ 18 years old at disease onset;
  • 6. The partner is ≥ 18 years old;
  • 7. Both couple members live together;
  • 8. Both couple members have good command of the Dutch language (checked implicitly during registration);
  • 9. Both couple members have adequate computer literacy and have access to an internet-connected computer, laptop or tablet (based on self-report);
  • 10. Both couple members agree to participate in the research.
  • Exclusion Criteria:
  • The couple will be excluded in case:
  • 1. The patient is currently following an evidence-based therapy for CCRF (i.e. Cognitive-Behavioral Therapy, mindfulness-based therapy, exercising/physiotherapy) as self-reported at the (telephone) screening;
  • 2. The patient suffers from a condition that can explain his/her fatigue and is potentially treatable (e.g. anemia);
  • 3. The therapist decides, based on information collected during the intake session, that the intervention is not suitable for the couple. Criteria that will be considered include, but are not limited to:
  • presence of severe psychiatric morbidity such as suicidal ideation and/or psychosis (as assessed by the therapist at the intake session). Mild depression is not an exclusion criterion. A score of ≥ 20 on the Hospital Anxiety and Depression Scale (HADS) at T0 is considered indicative of depression. Therefore, if the patient or the partner scores ≥ 20, the therapist will determine at the intake whether the participant has suicidal ideation or suffers from other severe psychiatric morbidity. A participant (and thus the couple) will be excluded if, according to the therapist, that is the case;
  • presence of substance abuse, except for smoking.

Trial Officials

Mariët Hagedoorn, PhD

Principal Investigator

University Medical Center Groningen

About Mariët Hagedoorn

Mariët Hagedoorn is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative study designs and rigorous scientific methodologies. With a focus on enhancing therapeutic interventions, Mariët Hagedoorn collaborates with leading researchers and healthcare professionals to ensure the highest standards of clinical practice. By prioritizing patient safety and ethical considerations, the organization aims to contribute valuable insights to the medical community and facilitate the development of effective treatments across various therapeutic areas.

Locations

Groningen, , Netherlands

Groningen, , Netherlands

Bilthoven, , Netherlands

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials